FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases “The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives ...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform ...
Revvity, Inc. (NYSE:RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, ...
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST ...
Tuberculosis, or TB, is a disease that infects nearly 11 million people worldwide, killing some 1.25 million of them every year, per data from the World Health Organization. A person infected with the ...
(RTTNews) - Revvity, Inc. (RVTY), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. tuberculosis (TB) test. "The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback